SOPHiA GENETICS SA
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SOPH | TEM | NEO | MYGN | IMDX | PSNL | |
|---|---|---|---|---|---|---|
| Market cap | 597.04M | 13.79B | 2.22B | 575.81M | 86.72M | 1.69B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -13.9 | -13,335.1 | 54.5 | -10.2 | -3.3 | -16.3 |
| Price/book | 8.6 | 27.5 | 2.8 | 1.9 | -4.1 | 6.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +52.88% | +4.88% | +61.36% | −4.90% | −58.86% | +119.76% |
| Today | +0.87% | −2.81% | +1.90% | −0.33% | −3.28% | +0.25% |
The closest companies by business and industry (Health Information Services). Prices may be delayed up to 15 min.
Latest news
All SOPH news ›SOPHiA GENETICS reports 25% revenue growth and holds sales range
Genomic analysis volume reached a record 118,000 as the company narrowed its adjusted EBITDA loss and targeted the upper end of annual guidance. Revenue grew 25 per cent to US$24.3 million as SOPHiA GENETICS SA NASDAQSOPH reported…
SOPHiA GENETICS SA (SOPH) Q3 2026 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Kellen Sanger - Head of Strategy and Investor RelationsRoss Muken - CEO & DirectorGeorge Cardoza - Executive VP & CFO Mark Massaro - BTIG, LLC, Research…
Sophia Genetics Sees Global Markets Lift Q3 Revenue 25 Percent
Sophia Genetics Sees Global Markets Lift Revenue 25 Percent in Q3 GenomeWeb Sophia Genetics Sees Global Markets Lift Revenue 25 Percent in Q3
SOPHiA GENETICS Reports Third Quarter 2026 Results
Nov 03, 2026, 06:45 ET BOSTON and ROLLE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30,…
SOPHiA GENETICS SA (NASDAQ:SOPH) Stock Has Consensus Target Price of $10.00
MarketBeat SOPHiA GENETICS SA (NASDAQ:SOPH) Stock Has Consensus Target Price of $10.00 - Analysts have a mixed view of SOPHiA GENETICS: five analysts give the stock an average “Hold” rating, with three buys, one hold and on
SOPHiA GENETICS (SOPH) Projected to Release Quarterly Earnings on Tuesday
Posted by Defense World Staff on Nov 1st, 2026 Read Our Latest Research Report on SOPHiA GENETICS SOPHiA GENETICS SA is a healthcare technology company that develops data-driven solutions for genomic medicine. Its cloud-based platform uses…
Sophia Genetics SA SOPH
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data…
SOPHiA GENETICS (NASDAQ:SOPH) Sees Strong Trading Volume - Here's What Happened
SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) shares saw unusually-strong trading volume on Thursday. 1,175,730 shares changed hands during mid-day trading, an increase of 275% from the previous session's volume of 313,782 shares. The…
SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $28,720.00 in Stock
Zhenyu Xu also recently made the following trade(s): Read Our Latest Stock Report on SOPH SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketbeat.com6
- defenseworld.net3
- stocktitan.net3
- prnewswire.com2
- businessnewsthisweek.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 23 articles, not a forecast.